Best in Biotech 12 Dec 2017 Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017 As 2016 was a tough year for biotech, 2017 was under pressure to turn things around. Although there has been an improvement, there were some notable speed bumps for the industry. 2017 started brightly, with 14 FDA approvals by April – a big improvement on 2016, which only saw 22 in the whole year. The […] December 12, 2017 - 7 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Belgian Antibody Proves Effective to Treat Myasthenia Gravis A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease […] December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech ADC Therapeutics is one of our top biotechs of the year after it brought in a massive $200M (€170M) fundraising round. The company develops antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Results from two Phase I studies […] December 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations? Mereo BioPharma’s drug, BCT-197, more than halved the number of hospitalizations of chronic obstructive pulmonary disease patients during a Phase II trial. Mereo BioPharma develops therapies for patients with rare diseases. Today, it has announced that BCT-197, or acumapimod, improved lung function and reduced the number of hospitalizations for treatment in chronic obstructive pulmonary disease (COPD) patients. One of […] December 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 11 Dec 2017 Edwin Moses on how Ablynx has made it to the top of European biotech Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […] December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2017 Wilson’s Disease Treatment Gets a €24.4M Equity Boost in Sweden Wilson Therapeutics has issued new shares on Nasdaq Stockholm, raising a total of SEK 244M (€24.4M) to help bring its Wilson’s disease treatment to the market. Stockholm-based biotech Wilson Therapeutics has closed a share issue that seems to have generated quite a high demand. The company’s main shareholders, Abingworth and MVM, had to sell SEK 156.75M […] December 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2017 A London Biotech Aims to Overtake the Dry Eye Syndrome Market TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.” Based in London, the biotech company TopiVert is trying to enter the $3Bn market of dry eye syndrome with a drug with the potential to work better than the options currently […] December 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2017 French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia Erytech’s candidate, Graspa, has been unable to significantly improve overall survival in patients with acute myeloid leukemia during a Phase IIb trial. Erytech, based in Lyon, France, has developed an interesting approach to delivering drugs for the treatment of cancer and orphan diseases. The company’s eryaspase technology, Graspa, encapsulates L-asparaginase, in red blood cells. Graspa was used in combination with chemotherapy […] December 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 Scottish Biotech and Bluebird Bio to Develop Next Generation CAR-T Cells TC Biopharm has scored a deal with bluebird bio for the development of the next generation of CAR-T cells, a technology giving new hope to cancer patients. With the first two CAR-T therapies now in the market, the way we treat cancer is changing. This technology has shown to be effective in a high percentage of patients […] December 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival A new first-line combination therapy for advanced non-squamous non-small-cell lung cancer improved progression-free survival during a Phase III trial. Scientists based at the Lung Clinic Grosshansdorf, Hamburg, and Centre Hospitalier Universitaire Vaudois, Lausanne, have presented the results of a Phase III study at the ESMO Immuno Oncology Congress 2017. The study was the first to investigate a combination […] December 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma Adocia’s rapid-action insulin outperforms Novo Nordisk’s market approved treatment for type 1 diabetes during a Phase I study. Adocia specializes in new formulations of therapeutic proteins, particularly for the treatment of diabetes. Just last week, Adocia’s glucagon treatment for hypoglycemia was proved to be safe in a Phase I study. Today, the biotech has announced that its […] December 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2017 CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug target for acute myeloid leukemia (AML) has been identified that could open new avenues for the development of new treatments against the deadly disease. Researchers from the Wellcome Trust Sanger Institute have […] December 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email